Experimental systemic cryptococcosis in immunocompetent animal model (BALB/c) and immunodeficient (BALB /c-SCID): Treatment with amphotericin B and fluconazole

E.G. da Silva1, S. de Souza1, C. Viani1, G.C.M. Batista1, V.K. Perinazzo1, R.A. Prates2, M.S. Ribeiro2, C.R. Paula1

Author address: 

IPEN, SíƒO PAULO, Brazil

Abstract: 

Background: Cryptococcosis is a disseminated fungal disease that occurs mainly in immunocompromised individuals, characterized by high mortality rates. This disease is caused by the yeast Cryptococcus neoformans. Systemic spread from a primary focus of cryptococcal infection commonly involves the central nervous system, manifested as meningitis or meningoencephalitis. The treatment of most infections is based on results of the sensitivity in vitro, these results may predict the clinical answer, and however, this answer depends on several factors intrinsic to the antifungal the host as well as pathogen versus host interaction. Objective: This study was evaluate, the efficacy antifungal therapy of fluconazole associated with amphotericin B in experimental systemic cryptococcosis in immunocompetent (BALB/c) and immunodeficient (BALB/c-SCID). Methods: the animals were inoculated through into the tail vein. The treatment was initiated one day after infection, and animals were treated daily for fifteen days. Results: The study demonstrated that immunocompetent and immunodeficient animals, treated for thirteen days and fifteen days respectively, survived the study period and brain tissue of these animals were free of Cryptococcus neoformans. Conclusion: the present results suggest that the combination amphotericin B (1.5μg/kg/day) and fluconazole (30.0μg/kg/day) was effective in the treatment of cerebral cryptococcosis in two models studied.
2009

abstract No: 

P322

Full conference title: 

4th Trends in Medical Mycology
    • TIMM 4th (2012)